1.
Clin Infect Dis
; 35(6): 760-2, 2002 Sep 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12203175
RESUMO
We compared seminal plasma pharmacokinetic data for the investigational amprenavir prodrug GW433908 with those for amprenavir and an amprenavir-ritonavir combination regimen. All 3 regimens resulted in detectable blood plasma and seminal plasma concentrations of amprenavir. The majority of these concentrations were greater than the plasma protein-corrected 50% inhibitory concentration for wild-type human immunodeficiency virus type 1.